UPCC 54419: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Recruiting
99 years or below
All
1 Location

Brief description of study

This study enrolls subjects with relapsed or refractory CD30-positive Peripheral T-cell Lymphoma (PTCL) or Transformed Mycosis Fungoides (TMF). The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. This study is divided in three cohorts, depending on diagnosis and the level of a tumor marker. About 145 participants are expected to participate in this study around the world.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 01 Jun 2021. Study ID: 835016

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.